Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Myelo Therapeutics

Request full access

Innovative treatments in areas of high unmet medical needs

Berlin, GermanyFounded 2013Biotech & Life Sciences

About Myelo Therapeutics

Myelo Therapeutics GmbH is a Berlin-based clinical-stage pharmaceutical company established in 2013, concentrating on the development of treatments for conditions with significant unmet medical needs. The company was acquired by Eckert & Ziegler Strahlen- und Medizintechnik AG in December 2022 and now operates as a fully owned subsidiary.

The firm's primary focus is on its lead compound, Myelo001, an orally administered small molecule designed to address myelosuppression—a reduction in blood cell production—which is a common and severe side effect of chemotherapy and radiotherapy. Myelosuppression can lead to treatment interruptions and heightened risk of infection, potentially compromising the effectiveness of cancer therapies. Myelo001 works by protecting immature granulocytic cells and promoting the maturation of neutrophils, which are crucial white blood cells for fighting infection. The product is being investigated for treating chemotherapy-induced myelosuppression (CIM), radiation-induced myelosuppression (RIM), and as a medical countermeasure for Acute Radiation Syndrome (ARS) resulting from nuclear incidents.

Myelo Therapeutics operates through a combination of in-house research and strategic collaborations with contract research organizations and universities. The development of Myelo001 has received significant support, including contracts from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), valued at up to $6.5 million, and grants from the European Defence Fund. The company has successfully navigated key regulatory milestones, including a Pre-Investigational New Drug (IND) meeting with the U.S. FDA and has received Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA) for the treatment of ARS.

Clinical trials have been a central part of the company's progression. A Phase IIa study was initiated to evaluate the efficacy and safety of Myelo001 in reducing chemotherapy-induced neutropenia in breast cancer patients. The business model is centered on advancing Myelo001 through the clinical and regulatory pipeline toward market authorization, targeting a global market for supportive cancer care estimated at USD 8 billion. Key investors prior to its acquisition included Eckert Life Science Accelerator, IBB Ventures, and JSC Valenta Pharmaceuticals.

Source: Dealroom company data

Myelo Therapeutics in the Berlin ecosystem

Live from Dealroom

The Myelo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • European Commission

Series A1 investor entered at this stage

  • IBB Ventures
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇩🇪 Germany100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Myelo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Myelo Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.